# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $17 t...
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industria...
Expect 10 Clinical Readouts In 18 Months, $200M In Milestone Payments Over 24 Months, $20B Potentially Overall, $850M Cash On H...
Keybanc analyst Scott Schoenhaus maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price ta...
Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwri...